FoxHollow: Reviving Atherectomy

The ideal treatment for coronary artery disease is to remove the obstructing plaque, for which several de-bulking technologies, including atherectomy, were developed. The stent revolution of the mid-1990s provided an easier-to-use therapy with more consistent outcomes, relegating de-bulking tools to niche technologies. Physician/entrepreneur John Simpson, who developed the initial atherectomy technology at Devices for Vascular Intervention, remains committed to the principle that it is better to remove plaque than stent it. He believes the next-generation atherectomy device developed at his new company, Fox Hollow, will be a viable treatment option to compete with stenting, including the new generation of drug-eluting stents. Fox Hollow recognizes the need to fight the atherectomy adoption battle on both the ease-of-use and the clinical outcomes fronts, with the latter being particularly important as interventionalists look increasingly to clinical trials in making their product choices. But drug-eluting stent proponents don't believe it is possible to achieve comparable outcomes.

By Stephen Levin

Last year's American Heart Association meeting included a presentation on niche devices in interventional cardiology, which featured leading interventionalists discussing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy